HOLON, Israel, October 10, 2016 /PRNewswire/ --
Compugen Ltd. (NASDAQ: CGEN), a leading
predictive drug discovery company, today announced that the Company
will issue its quarterly financial statements for the third quarter
2016 on Monday, November 7. The
Company also announced today that it will host its third quarter
conference call the following week, on
Wednesday, November 16,
2016 at 10:00 am ET.
On Friday,
October 7, 2016, the Company announced that John Hunter, Ph.D., Site Head and Vice
President, Antibody R&D, Compugen USA, Inc., will present data on the Company's
CGEN-15029 novel immune checkpoint program on Friday, November 11 at 11:45 am ET, at the 31st Annual Meeting of
the Society for Immunotherapy of Cancer (SITC) at the Gaylord
National Hotel & Convention Center in National Harbor,
Maryland. The Company also plans
to issue a separate press release with respect to such data.
The third quarter conference call is
being postponed to the week following the release of the financial
statements in order to include discussion of the CGEN-15029 data
during the call. Information regarding accessing this quarterly
call will be provided in advance of the call.
About Compugen
Compugen is a leading therapeutic
discovery company utilizing its broadly applicable predictive
discovery infrastructure to identify novel drug targets and develop
first-in-class biologics. The primary focus of the Company's
current pipeline is on immune checkpoint target candidates
discovered by the Company, potentially providing the basis for a
next wave of therapeutics for cancer immunotherapy. Compugen's
business model is based on selectively entering into collaborations
for its novel target candidates and drug product candidates at
various stages of research and development under revenue-sharing
agreements. The Company is headquartered in Israel, with R&D facilities in
Israel and South San Francisco. At
the US facilities, monoclonal antibody therapeutic candidates are
discovered and developed against the Company's novel target
candidates. For additional information, please visit Compugen's
corporate website at http://www.cgen.com.
Forward-Looking Statement
This press release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by the use of terminology such as
"will," "may," "expects," "anticipates," "believes," and "intends,"
and describe opinions about future events. These forward-looking
statements involve known and unknown risks and uncertainties that
may cause the actual results, performance or achievements of
Compugen to be materially different from any future results,
performance or achievements expressed or implied by such
forward-looking statements. Among these risks: Compugen's business
model is substantially dependent on entering into collaboration
agreements with third parties, and Compugen may not be successful
in generating adequate revenues or commercializing aspects of its
business model. Moreover, the development and commercialization of
therapeutic candidates involve many inherent risks, including
failure to progress to clinical trials or, if they progress to or
enter clinical trials, failure to receive regulatory approval.
These and other factors are more fully discussed in the "Risk
Factors" section of Compugen's most recent Annual Report on Form
20-F as filed with the Securities and Exchange Commission as well
as other documents that may be subsequently filed by Compugen from
time to time with the Securities and Exchange Commission. In
addition, any forward-looking statements represent Compugen's views
only as of the date of this release and should not be relied upon
as representing its views as of any subsequent date. Compugen does
not assume any obligation to update any forward-looking statements
unless required by law.
Company contact:
Tsipi Haitovsky
Global Media Liaison
Compugen Ltd.
Email: tsipih@cgen.com
Tel: +972-52-598-9892
SOURCE Compugen Ltd.